Rationale: Cardiomyocyte apoptosis is one of the key events in the development and progression of heart failure, and a crucial role for ICER (inducible cAMP early repressor) in this process has been previously reported. ERK5 is known to inhibit cardiac apoptosis after myocardial infarction (MI), especially in hyperglycemic states, via association with CHIP ubiquitin (Ub) ligase and subsequent upregulation of CHIP ligase activity, which induces ICER ubiquitination and subsequent protein degradation. The regulatory mechanism governing ERK5/CHIP interaction is unknown.
increased in diabetic mice after MI (DMϩMI), and this increase in ICER levels was blunted in transgenic mice expressing a cardiac-specific constitutively active form of MEK5␣ (CA-MEK5␣-Tg). 12 This finding provides a mechanistic framework for understanding the cardioprotective action of ERK5 in DMϩMI mice via downregulation of ICER levels and inhibition of apoptosis.
In a subsequent study we demonstrated that ubiquitination was a critical regulatory mechanism linking ERK5 activation and ICER reduction in DM mice. ERK5 positively regulated chaperone-dependent E3 ubiquitin (Ub) ligase CHIP (carboxyl terminus of Hsp70-interacting protein)-mediated ICER ubiquitination and subsequent protein degradation. This downregulation of ICER levels leads to maintaining Bcl-2 at high levels, and protects cells from apoptosis. Our studies showed that cardiac CHIP Ub ligase activity was significantly decreased after DMϩMI and this decrease was rectified in CA-MEK5␣-Tg mice. 13 However, the regulatory mechanism underlying this reduction of CHIP Ub ligase activity in DMϩMI mice and how ERK5 activation reversed this phenomenon remains unclear.
In this study, we show that the ERK5-CHIP module is one of the major targets of p90RSK in diabetic hearts. Our data strongly suggest that the activation of p90RSK abrogates ERK5-mediated CHIP Ub ligase activation, and accelerates apoptosis and cardiac dysfunction in the DMϩMI condition.
Methods
Additional information regarding animals, antibodies and reagents, plasmids, adenovirus construction, cell culture, mammalian 2-hybrid analysis, immunoprecipitation, western blotting, p90RSK in vitro kinase assay, in vitro ubiquitination assay with GST-ICER, permanent coronary ligation surgery, streptozotocin (STZ) injection, apoptosis assay, echocardiographic analysis, liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) analysis of ERK5 phosphorylation by p90RSK, and statistics can be found in the online-only Data Supplement.
Results

Angiotensin II Upregulates the ICER Protein Levels and Promotes Apoptosis of Cardiomyocytes via P90RSK Activation
Angiotensin II (Ang II) plays a pivotal role in the exacerbation of heart failure in patients with diabetes after MI. 14 -16 In these patients the ICER protein levels and apoptosis in cardiomyocytes are enhanced, 17, 18 and p90RSK is also activated. 19 p90RSKs are a family of serine/threonine kinases, activated by various stimuli including ischemia, 20, 21 reactive oxygen species, [22] [23] [24] [25] Ang II, 19, 26, 27 and DM. 24 Because ICER is important in the regulation of cardiomyocyte apoptosis, 12 we have examined whether p90RSK modulates apoptosis via regulation of the ICER protein level. First, we confirmed that Ang II activated p90RSK in cardiomyocytes (Online Figure I, A  and B) . Similarly, high glucose (25 mmol/L) also activated p90RSK, whereas mannitol (25 mmol/L), which served as a hyperosmolar control, did not (Online Figure I, C and D) .
Next, we investigated the involvement of p90RSK activation in cardiomyocyte apoptosis as assayed by TUNEL (terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling) staining. When cardiomyocytes were treated with Ang II, both ICER levels ( Figure 1A and 1B) and the number of TUNELpositive cells ( Figure 1E and 1F) increased. However, these increases were inhibited in cells transduced by an adenovirus expressing dominant negative p90RSK (Ad-DN-p90RSK) (Figure 1A and 1B and Figure 1E and 1F).
In addition to overexpressing dominant negative p90RSK, we also used 1-(4-amino-7-(3-(2-methoxyethylamino) proxyl)-5-p-tolyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-2-fluoroethanone (FMK-MEA) which is a water-soluble derivative of the previously reported fluoromethyllketone, a selective p90RSK inhibitor. 28, 29 Ang II-induced increase in the ICER levels and apoptosis assayed by cleaved caspase 3 expression were significantly inhibited in cardiomyocytes treated by FMK-MEA ( Figure 1C and 1D), also supporting the obligatory role of p90RSK activation in these Ang II-mediated effects. We confirmed that Ang II-mediated p90RSK activation was significantly inhibited by Ad-DN-p90RSK transduction and FMK-MEA treatment (Online Figure II ). Furthermore, we performed the converse experiment using Ad-WT-p90RSK and found higher ICER levels in cardiomyocytes (Online Figure III, B) , also confirming an obligatory role for p90RSK in regulating ICER levels. 
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Activation of p90RSK Reduces CHIP Ub Ligase Activity Induced by Ang II In Vitro and After Myocardial Infarction in Diabetic Mice In Vivo
ERK5-CHIP association is critical for the upregulation of CHIP Ub ligase activity, leading to the ubiquitination and subsequent proteosomal degradation of ICER. 13 Since p90RSK activation was crucial for an Ang II-mediated increase in ICER levels, we investigated whether p90RSK could negatively regulate CHIP Ub ligase activity and thereby stabilize the ICER protein. To detect CHIP Ub ligase activity, we performed an in vitro ubiquitination assay using a GST-ICER fusion protein as a substrate. 13 CHIP Ub ligase activity was significantly decreased after Ang II stimulation, and transduction with Ad-DN-p90RSK significantly inhibited this phenomenon ( Figure  2A and 2B). Next we investigated whether p90RSK activation could regulate ICER mRNA expression. As shown in Online Figure III, A, we found that Ang II increased ICER mRNA expression. However, we could not detect any inhibition of ICER mRNA expression by Ad-DN-p90RSK transduction. These data suggested that p90RSK activation regulates ICER levels at the posttranscriptional rather than the transcriptional level.
Since CHIP Ub ligase activity requires ERK5-CHIP interaction, 13 and since Ang II regulates this process by activating p90RSK, we examined whether Ang II-mediated p90RSK activation could regulate ERK5-CHIP interaction. In quiescent cardiomyocytes, ERK5 activity regulates the association of ERK5 with CHIP. 13 Indeed, we found that the ERK5-CHIP Immunoblotting with anti-CHIP (2nd from top) and anti-ICER antibody (3rd and 4th from top) after in vitro CHIP Ub ligase assay suggested that the Ub bands we observed in this assay, especially above 120 kDa, are mainly due to the ubiquitination of GST-ICER but not from GST, IgG, or endogenous CHIP as described in the method. B, Quantifications of relative CHIP Ub ligase activity from 3 independent experiments (meanϮSD, nϭ3, *PϽ0.05 compared with the Ad-LacZ and untreated control). Results are expressed as the relative ratio of untreated cells in the LacZ control. C, P90RSK activation inhibited ERK5-CHIP association. Cardiomyocytes were transduced with Ad-DN-p90RSK or Ad-LacZ for 24 hours, followed by 45 minutes of Ang II stimulation. Cell lysates were immunoprecipitated with anti-CHIP and immunoblotted with anti-ERK5. Expression of ERK5, CHIP, and Flag-tagged DN-p90RSK was detected by Western blotting using each specific antibody. D, Relative coimmunoprecipitated ERK5 band intensities from 3 independent experiments were quantified (meanϮSD, nϭ3, *PϽ0.05, compared with untreated control). Results are expressed as fold decrease in ERK5 band intensity in Ang II-treated cells that are expressing either Ad-LacZ or Ad-Flag-DN-p90RSK compared with untreated cells. association was significantly decreased by stimulation of cardiomyocytes with Ang II (Figure 2C and 2D) and Ad-DN-p90RSK transduction blocked this decrease in cells treated with Ang II ( Figure 2C and 2D). These results indicated a key role for p90RSK in the reduction of ERK5-CHIP association, and subsequent inhibition of CHIP Ub ligase activity in cells stimulated with Ang II.
To explore the role of p90RSK activation in the reduction of CHIP Ub ligase activity in vivo, we utilized the cardiacspecific DN-p90RSK-Tg mice. These mice showed relative resilience to cardiac ischemia/reperfusion injury, 30 therefore we examined the effects of inhibiting p90RSK in diabetic mice after MI. The cardiac function of DN-p90RSK-Tg mice was unaltered, 30 and the ICER levels in these transgenic were similar to that of nontransgenic littermate control (NLC) sham operated mice (Online Figure IV, A) . Mice were rendered diabetic by intraperitoneal injection of STZ. On day 7 after STZ injection, both NLC and DN-p90RSK-Tg mice showed elevated random blood sugar levels with similar body weight (Online Figure V, B) . We have previously shown that preoperative insulin-treatment of STZ-injected mice stabilizes cardiac function after MI, suggesting myocardial derangement in diabetic mice after MI is a function of hyperglycemia rather than a toxicity artifact of STZ. 31 The role of p90RSK activation in regulating CHIP Ub ligase activity, subsequent ICER levels and cardiomyocyte apoptosis in vivo were examined. As shown in Figure 3A Figure VI ). Because CHIP Ub ligase activity regulates ICER protein stability in heart failure, 12, 13 we examined the ICER protein level as well as the abundance of downstream ICER mediators, such as Bcl-2 10 and SERCA2. 32 In NLC mice, we found increased ICER levels and a concomitant reduction in Bcl-2 expression after MI in diabetic mice and this was rescued in DN-p90RSK-Tg diabetic mice after MI ( Figure 3A , 3B, and 3D). SERCA2 expression was also reduced in NLC diabetic mice after MI. However, the reversal of this effect in DN-p90RSK diabetic mice after MI is less obvious ( Figure  3B and 3D). Interestingly, the level of ERK5 phosphorylation at T218 and Y220 was decreased slightly in DN-p90RSK diabetic mice after MI ( Figure 3C ), suggesting a role for activated p90RSK in phosphorylating ERK5 T218/ Y220-the same residues phosphorylated by MEK5 responsible for ERK5 activation.
TUNEL-positive cells significantly increased in diabetic NLC mice after MI when compared with sham controls (Online Figure V, F and G), supporting the known role of cellular apoptosis in the development of heart failure. 33 Notably, reduced incidence of apoptosis was found in diabetic DN-p90RSK-Tg mice after MI (Online Figure V, F and G), suggesting a functional consequence for p90RSK activation in promoting cardiac apoptosis after MI in diabetic animals.
p90RSK Activation Inhibits ERK5-CHIP Association via Competitive Binding With ERK5 and Direct Phosphorylation of ERK5-S496
On activation, ERK5 exerts its cardioprotective effect by promoting ERK5-CHIP binding, which increases CHIP Ub ligase activity. 13 Because there is a role for p90RSK activation in Ang II-mediated disruption of ERK5-CHIP binding and subsequently reduction of CHIP Ub ligase activity ( Figures 1 and 2) , we investigated how p90RSK regulates ERK5-CHIP association. To determine the protein domain of ERK5 responsible for the p90RSK-ERK5 and ERK5-CHIP interaction, we generated three truncated ERK5 fragments and evaluated their association with p90RSK ( Figure 4A ) and CHIP ( Figure 4B ), using a mammalian 2-hybrid assay. A plasmid containing GAL4-DBD (DNA binding domain) and the full-length p90RSK ( Figure 4A ) or CHIP ( Figure 4B ) were constructed in the pBIND vector; plasmids to express VP16-ERK5 (full-length or truncated forms) were constructed in the pACT vector. Constitutively active MEK5␣ (CA-MEK5␣) induces forced activation of ERK5 and significantly increases ERK5-CHIP association by decreasing the inhibitory effect of the NH 2 -terminal kinase domain of ERK5. This ERK5-CHIP association at the helical linker domain of CHIP is fundamental for increasing CHIP Ub ligase activity. 13 Therefore, we examined the effect of CA-MEK5␣ expression on the association of ERK5 and CHIP. The mammalian 2-hybrid assay demonstrated that the NH 2 -terminal region of ERK5 (aa1-148) and the COOH-terminal region of ERK5 (aa571-807) associate with CHIP ( Figure 4A and 4B). The latter site overlaps with the p90RSK binding site.
To examine whether the wild-type p90RSK and the ERK5 fragment (ERK5-Fr, aa571-807) alter ERK5-CHIP association in vitro, we used an overexpression system. Because CHIP binding site is within the ERK5 aa571-807 region, we focused on ERK5-Fr (aa571-807). ERK5-CHIP binding was increased by CA-MEK5␣ ( Figure 4C, lane 3) . Overexpression of both wild-type p90RSK and ERK5-Fr inhibited ERK5-CHIP association ( Figure 4C , lane 5-6, and Online Figure VII , A and B), suggesting that the ability of WT p90RSK to inhibit ERK5-CHIP association was due to competition between p90RSK and ERK5 for the same binding site on CHIP ( Figure 8E ).
Since p90RSK inhibits ERK5-CHIP association via competitive binding with ERK5, we have investigated whether Ang II-mediated p90RSK activation is required for p90RSK-ERK5 association in cardiomyocytes. Ang II increased p90RSK-ERK5 binding, and this was significantly inhibited by FMK-MEA ( Figure 4D and 4E) . As p90RSK activation induced by Ang II increased p90RSK-ERK5 binding, we determined the role of p90RSK activation in ERK5-CHIP binding. Wild-type p90RSK but not DN-p90RSK completely inhibited ERK5-CHIP association ( Figure 4C , lane 4 -5, and Online Figure VII, C and D) , supporting the role of p90RSK activation in increased p90RSK-ERK5 association as well as decreased ERK5-CHIP association. Based on these results, we reasoned that because Ang II induced p90RSK but not ERK5 activation (Online Figure VIII) , the regulation of ERK5-CHIP binding mediated by p90RSK activation probably occurs by a process that requires direct interaction of the 2 without ERK5 enzymatic activity being activated ( Figure 8E ).
Since p90RSK can associate with ERK5, we asked whether p90RSK directly phosphorylated ERK5 and as a consequence inhibited CHIP Ub ligase activity. To test this possibility, we performed an in vitro kinase assay by incubating recombinant p90RSK with GST-tagged-ERK5 fragments and found that p90RSK phosphorylated two ERK5 fragments (aa401-600 and aa601-816) ( Figure  5A ). In addition, LC-MS/MS analyses identified ERK5-S496 as being directly phosphorylated by p90RSK ( Figure  5B and 5C). To determine whether ERK5-S496 phosphorylation is involved in the Ang II-mediated reduction of CHIP Ub ligase activity in cardiomyocytes, we generated an adenovirus expressing the ERK5-S496A mutant (Ad-ERK5-S496A). Cardiomyocytes were transduced with Ad-ERK5-S496A, Ad-ERK5-WT, or Ad-LacZ, followed by Ang II stimulation. Cell lysates were then subjected to an in vitro CHIP ubiquitination assay using a GST-ICER fusion protein as a substrate. Ang II inhibited CHIP Ub ligase activity in cardiomyocytes transduced by Ad-LacZ or Ad-ERK5-WT. In contrast, Ad-ERK5-S496A transduction abolished this inhibitory effect on CHIP Ub ligase activity ( Figure 5D and 5E ). In addition, the Ang IImediated increase in ICER levels was significantly inhibited in cardiomyocytes overexpressing Ad-ERK5-S496A mutant, but not in those expressing the Ad-ERK5-WT or Ad-LacZ ( Figure 5F and 5G) . These findings indicate that p90RSK-mediated ERK5-S496 phosphorylation is required for inhibiting CHIP Ub ligase activity ( Figure 8D and 8E).
Cardiac-Specific ERK5 Knockout Mice Showed Reduced CHIP Ub Ligase Activity After MI
To corroborate the necessity of ERK5 activation in increasing CHIP Ub ligase activity and subsequent reduction of ICER, we used ERK5 knockout mice (ERK5-CKO). Because ERK5 activation is cardioprotective 13 and ERK5-CKO mice displayed significantly increased levels of cardiac dysfunction after MI under the non-DM condition ( Figure 6A , 6B and 6C), we subjected the mice to MI only. No basal cardiac abnormality was found in ERK5-CKO mice as we reported previously, 34 and no increase in ICER levels was observed (Online Figure IV, B) . After MI, ERK5-CKO mice showed a significant reduction in CHIP Ub ligase activity, and an increase in ICER levels ( Figure 6F and 6G) compared with the NLC mice. As expected, the ERK5-CKO mouse hearts showed a significant increase in the number of TUNELpositive cardiomyocytes compared with the NLC group ( Figure 6D and 6E) . These data further confirmed the importance of ERK5 in regulating CHIP Ub ligase activity and subsequent ICER levels and apoptosis in vivo ( Figure  8D ). Because a difference in the infarct size may correlate A and B) and full-length p90RSK (A) or CHIP (B) fused to the Gal4 binding domain were cotransfected with the Gal4-responsive luciferase reporter pG5-luc. The total transfected DNA amount was normalized with empty VP16 vector. Binding affinity was assayed by luciferase activity normalized by the renilla luciferase activity. Data are representative of 3 independent experiments. **PϽ0.01, meanϮSD, nϭ3. C, Both wild-type p90RSK (WT-p90RSK) and ERK5-Fr (aa571-807) but not DN-p90RSK disrupted ERK5-CHIP association. After plasmid transfection as indicated, immunoprecipitated ERK5 was immunoblotted with anti-CHIP. Protein expression was determined by immunoblotting with each specific antibody. The blots are representative of data obtained from at least 3 different blots. D, Ang II increased p90RSK-ERK5 interaction via p90RSK activation. Cardiomyocytes were stimulated with Ang II after 3 hours of FMK-MEA pretreatment. Immunoprecipitated ERK5 was immunoblotted with anti-p90RSK. Each protein expression was detected as described in C. E, Relative p90RSK-ERK5 binding was quantified as described in Figure 2D . *PϽ0.05, meanϮSD, nϭ3.
with post-MI cardiac dysfunction, we compared the permanent coronary ligation-mediated infarct size between NLC (C57BL/6) and ERK5-CKO mice. As shown in Online Figure IX we did not find any difference in the infarct size among these groups, although we found significant cardiac dysfunction and an increase in lung weight/TL in ERK5-CKO mice.
Reduction of CHIP Ub Ligase Activity and Increased ICER Levels Were Observed in WT-p90RSK-Tg Mice After MI But Were Significantly Inhibited in WT-p90RSK-Tg/Constitutive Active MEK5␣ Double Transgenic Mice
Thus far, we have shown the critical role of the p90RSK-ERK5 module in CHIP Ub ligase activity and ICER levels in Cardiomyocytes were transduced with either Ad-ERK5-WT, Ad-ERK5-S496A mutant, or Ad-LacZ for 24 hours followed by 2 hours of Ang II stimulation as indicated. E, Relative CHIP Ub ligase activity was quantified as described in Figure 2B (**PϽ0.01, *PϽ0.05, meanϮSD, nϭ3). F, Ang II-mediated ICER induction was inhibited by ERK5-S496A mutant. Cardiomyocytes were transduced as described in D followed by 24 hours of Ang II stimulation. G, Quantification of ICER expression as described in Figure 1B Figure 2B and Figure 1B (**PϽ0.01, *PϽ0.05, meanϮSD, nϭ3). D, Model of DMϩMI or Ang II-mediated p90RSK-ERK5-CHIP signal transduction pathway that regulates cardiac apoptosis and subsequent cardiac dysfunction. E, Scheme depicting p90RSK-mediated regulation of the ERK5-CHIP module. At the basal level, inactive p90RSK inhibits the D-domain to bind with ERK5. 38 P90RSK-free ERK5 associates with CHIP at its linker and U-box domain and maintains its CHIP Ub ligase activity to prevent ICER induction and subsequent apoptosis. 13 However, once p90RSK is activated, the inhibition of the kinase domain is released 38 and the D-domain of p90RSK associates with the ERK5 COOHterminal domain, leading to compete with ERK5-CHIP association and ERK5-S496 phosphorylation, which disrupts ERK5-CHIP interaction. The disruption of ERK5-CHIP interaction inhibits CHIP Ub ligase activity, 13 increases ICER induction, and induces apoptosis. 13, 10 vitro, but the role of this module in vivo remains unclear. To clarify the function of the p90RSK-ERK5 signaling cascade in vivo, we crossed WT-p90RSK-Tg mice with those expressing constitutive active MEK5␣ (CA-MEK5␣-Tg) to generate double transgenic mice (Double-Tg). Cardiac function is normal in CA-MEK5␣-Tg and WT-p90RSK-Tg mice at 8 to 12 weeks of age as we previously described. 35, 36 Double-Tg also shows normal cardiac function (fractional shortening %ϭ67.7Ϯ3.7, nϭ3). No increase in ICER levels was observed in WT-p90RSK-Tg or Double-Tg mice (Online Figure IV, A) . Nondiabetic mice were subjected to a simple MI. After MI, the mortality of WT-p90RSK-Tg mice was significantly greater than NLC mice. The mortality of Double-Tg was similar to NLC mice ( Figure 7A ). There was no difference in body weight among the 3 groups ( Figure 7B ). One week after MI, the LV weight/TL and lung weight/TL ratios were higher in WT-p90RSK-Tg mice compared with NLC mice (Figure 7C and 7D) but lower in Double-Tg mice compared with WT-p90RSK-Tg mice ( Figure 7C and 7D). Myocardial contractile function as assessed by echocardiography was diminished in WT-p90RSK-Tg mice compared with NLC after MI ( Figure 7E ). Myocardial contractile function as assessed by echocardiography was preserved in Double-Tg mice ( Figure 7E ). We previously reported that CA-MEK5␣-Tg mice develop contractile dysfunction 1 week after simple MI. 31 In contrast, we found that activation of ERK5 by CA-MEK5␣ could reverse the detrimental effect of p90RSK activation on cardiac function after a simple MI, consistent with the idea that p90RSK activation accelerates cardiac dysfunction and heart failure after MI, possibly via inhibiting ERK5 activity. We also assessed the infarct size after permanent coronary ligation in NLC (FVB) mice, in diabetic mice, and in Double-Tg mice. As shown in Online Figure IX we found no difference in infarct size among these 3 groups. However, we noted significant cardiac dysfunction and increase of lung weight/TL in diabetic mice after MI. These data suggest that the major difference in cardiac dysfunction observed after one week of MI stems from cardiac remodeling in the surrounding, noninfarcted area rather than simply from infarct expansion.
Next, we investigated the involvement of CHIP Ub ligase activity in regulating ICER levels. Compared with the sham NLC mice, WT-p90RSK-Tg mice have reduced CHIP Ub ligase activity 1 week after MI. In contrast, no decrease in CHIP Ub ligase activity was observed in Double-Tg mice ( Figure 8A and 8C ). The increase in ICER level and concomitant reduction in Bcl-2 expression in WT-p90RSK-Tg mice were also detected, and these changes were mostly reversed in Double-Tg mice (Figure 8A, 8B, and 8C ). Similar to NLC diabetic mice after MI ( Figure 3B and 3D) , SERCA2 expression was also reduced in WT-p90RSK-Tg mice after MI ( Figure 8B and 8C) . However, restoration of SERCA2 expression in Double-Tg mice after MI was observed ( Figure  8B and 8C) , contrasting what was observed DN-p90RSK diabetic mice after MI ( Figure 3B and 3D) .
Finally, WT-p90RSK-Tg mice have increased apoptosis one week after MI compared with sham NLC mice, and this phenomenon was reversed in Double-Tg mice ( Figure 7F and 7G). Taken together, ERK5 activation suppresses p90RSKmediated cardiac apoptosis after MI in vivo.
Discussion
In this study, we demonstrated a critical role for p90RSK activation in the reduction of CHIP Ub ligase activity and subsequent increase in the ICER protein levels ( Figure 8D and 8E). p90RSK activation promotes its association with ERK5 and phosphorylates it at S496. This phosphorylation appears to be a necessary and sufficient step in the ability of p90RSK to promote the dissociation of the ERK5-CHIP complex, which leads to reduced CHIP Ub ligase activity. The physiological significance of p90RSK activation in diabetic mice after MI lies in its ability to decrease CHIP Ub ligase activity. This mechanism is reversed in diabetic DN-p90RSK-Tg mice, which show increased CHIP Ub ligase activity and recovery of cardiac function.
Depletion of ERK5 inhibited CHIP Ub ligase activity and enhanced ICER levels after MI, suggesting a causal role of ERK5 in controlling CHIP Ub ligase activity and subsequent ICER stability. Supporting the role of ERK5 as a negative regulator of p90RSK-mediated CHIP Ub ligase inhibition, we demonstrate that diabetic WT-p90RSK-Tg mice exhibit diminished CHIP Ub ligase activity after MI, but that coexpressed CA-MEK5␣ in Double-Tg mice leads to restoration of CHIP Ub ligase activity, and prevents cardiac dysfunction, at least in part by preventing myocardial apoptosis.
Our studies focus on defining the molecular mechanism of cardiac dysfunction after MI, which is a prevalent but poorly understood consequence of diabetes. Therefore, we established a diabetic model of MI in which post-MI biochemical and physiological sequelae could be carefully examined in the immediate post-MI period. 31 We observed that p90RSK activation was significantly increased in DM. Consistent with our previous work in WT-p90RSK-Tg mice, we see cardiac dysfunction and significant fibrosis after 8 months of age-a phenotype similar to that seen in diabetic cardiomyopathy. 36 Furthermore, we found that DN-p90RSK-Tg mice do not have the same degree of cardiac dysfunction after MI in a diabetic model, supporting an important role for p90RSK in the development of cardiac dysfunction after MI in diabetes. The ability of p90RSK activation to decrease functionality of the ERK5-CHIP module suggests that cardiac-specific ERK5 knockout mice (ERK5-CKO) mimic the deleterious effect of diabetes on the heart. Therefore, we modeled MI only in WT-p90RSK-Tg ( Figure 8 ) and ERK5-CKO mice ( Figure 6 ). As mentioned above, we found that CHIP Ub ligase activity after MI was inhibited in ERK5-CKO mice compared with NLC mice. We also observed that CHIP activity in the sham operation group is much lower in C57BL/6 than FVB mice. The background of ERK5-CKO mice is C57BL/6, whereas the background of DN-p90RSK-Tg, WT-p90RSK-Tg, and Double-Tg is FVB. Therefore, this may explain why C57BL/6 mice are much more sensitive to MI than FVB strain and show much higher mortality after MI surgery. Further investigation will be necessary to clarify this issue.
Ranganathan et al 37 reported that the COOH-terminal domain of the D motif of p90RSK is an ERK5 binding site and that p90RSK activation was required for full association between p90RSK and ERK5. Consistent with this report, in our present study, we found that p90RSK activation is a key event in disrupting ERK5-CHIP interaction by (1) competitive binding of p90RSK to ERK5 causing displacement of CHIP from ERK5 and (2) phosphorylation of ERK5 at S496. Forced activation of ERK5 induced by insulin growth factor-1 or CA-MEK5␣ inhibits the association of p90RSK with ERK5. In addition, activated ERK5 significantly increases ERK5-CHIP association by relieving the inhibitory effect of the NH 2 -terminal kinase domain of ERK5 ( Figure 8D and 8E ). ERK5-CHIP association at the helical linker domain of CHIP is critical for increasing CHIP Ub ligase activity. 13 In support of this, the elevation of ERK5 activity in Double-Tg mice reversed the inhibitory effect of p90RSK activation on CHIP Ub ligase activity. Taken together, our data demonstrate that p90RSK activation influences the ability of its own COOH-terminus docking domain to bind ERK5 and phosphorylate residue S496. The p90RSK-ERK5 interaction and ERK5-S496 phosphorylation disrupt ERK5-CHIP association and decrease CHIP Ub ligase activity ( Figure 8D and 8E). It is possible that the association between p90RSK and ERK5 is necessary for p90RSK to phosphorylate S496 ERK5, or that p90RSK-mediated S496 phosphorylation of ERK5 leads to dissociation of p90RSK and ERK5. To determine which of these possibilities is true will require further investigation.
Our data show that p90RSK activation regulates ICER protein stability by regulation of CHIP Ub ligase activity. In support of this, (1) an ERK5-S496A mutant significantly inhibits Ang II-mediated reduction of CHIP Ub ligase activity and subsequent increase in ICER levels ( Figure 5 ), (2) CHIP is critical for ERK5-mediated decrease in ICER level, 13 and (3) depletion of CHIP increases ICER stability. 13 CHIP activity can regulate a variety of molecules including FOXO1, 38 ASK1, 39 and p53, 40, 41 and we cannot exclude the possibility that p90RSK can regulate the expression of these molecules via CHIP, and that dysregulation of these molecules contribute to cardiac dysfunction. In addition, p90RSK and ERK5 can also regulate proteins with CHIP and ICER-independent mechanism including Na ϩ /H ϩ exchanger, 19 renin-angiotensin system, 36, 42 and PPARs activities. 5, 43 Further investigation is necessary to clarify the role of these molecules in p90RSK/ERK5-mediated cardiac dysfunction, especially in DM, both in vitro and in vivo.
Naito et al reported that CHIP expression was decreased with concomitant upregulation of p53 expression within four days after MI. 41 In our study, there was no significant decrease in CHIP expression or increase in p53 expression at 7 days after MI in diabetic mice (data not shown). Instead, we found a significant decrease in CHIP Ub ligase activity in our diabetic mice after MI. The regulatory mechanism responsible for the downregulation of CHIP expression was not identified in the previous studies. 41 Our present study suggests a role for p90RSK activation in regulating ERK5-CHIP association and subsequent CHIP Ub ligase activation. Whether through an early decrease in CHIP expression or a later decrease in its Ub ligase activity, the net effect is promotion of the proapoptotic milieu contributing to poor functional recovery in diabetic mice after MI. Based on our results on the role of p90RSK-ERK5-CHIP described in our current work, ERK5 activation may reverse the decrease in Ub ligase activity and ameliorate cardiac dysfunction after MI in DM hearts.
Last, we close by commenting on the protective function of ERK5 after MI with or without superimposed DM. In this study, we showed that cardioprotective effect of ERK5 activation is particularly significant after MI in the context of DM. Previously, we reported that the cardiac function did not improve after 1 week of MI in the absence of DM in CA-MEK5␣-Tg mice compared with NLC mice. 31 These data suggest that ERK5 activation does not have a significant cardioprotective role in our MI model 1 week after permanent ligation. Although the role of ERK5 activation in cardiac remodeling after permanent ligation is limited, we found that cardiac protection was enhanced in hyperglycemic CA-MEK5␣-Tg mice, 31 suggesting that ERK5 activation has a significant role in DM after MI rather than being a consequence of MI per se, at least during the acute phase (within 1 week) after MI.
What New Information Does This Article Contribute?
• ERK5-CHIP module is one of the major targets of p90RSK in diabetic hearts. • Depletion of ERK5 inhibits CHIP Ub ligase activity and increases ICER levels after MI. • Diabetic wild-type p90RSK transgenic mice exhibit diminished CHIP Ub ligase activity after MI. However, when these mice coexpress a constitutively active form of MEK5␣ in double transgenic mice, CHIP Ub ligase activity is restored, also restoring cardiac dysfunction, at least in part by preventing myocardial apoptosis. • The activation of p90RSK abrogates ERK5-mediated CHIP Ub ligase activation, and accelerates apoptosis and cardiac dysfunction in the DMϩMI condition.
DM reduces survival after MI primarily due to acceleration of heart failure. We have found that the activation of p90RSK abrogates ERK5-mediated CHIP Ub ligase activation, and accelerates apoptosis and cardiac dysfunction in the DMϩMI condition. Our data demonstrate that p90RSK activation influences the ability of its own COOH-terminus docking domain to bind ERK5 and phosphorylate residue S496. The p90RSK-ERK5 interaction and ERK5-S496 phosphorylation disrupt ERK5-CHIP association and decrease CHIP Ub ligase activity. The regulatory mechanism responsible for the downregulation of CHIP expression after MI has not yet been identified. Our present study suggests a role for p90RSK activation in regulating ERK5-CHIP association and subsequent CHIP Ub ligase activation, either through an early decrease in CHIP expression or a later decrease in its Ub ligase activity The net effect is promotion of the proapoptotic milieu contributing to poor functional recovery in diabetic mice after MI. ERK5 activation may reverse the decrease in Ub ligase activity and ameliorate cardiac dysfunction after MI in DM hearts. Understanding the role and molecular mechanisms how p90RSK targets ERK5-CHIP ubiquitin E3 ligase activity should provide insights into mechanisms contributing to poor cardiac recovery after MI in DM and possibly reveal a novel therapeutic target.
